Article Details
Retrieved on: 2022-10-04 18:37:44
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Our firm belief in amyloid has driven our investment in developing therapeutics that target Abeta – including ACI-24 and our monoclonal antibody ...
Article found on: www.globenewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here